Cigacial beard: breakthrough in the treatment of IGA-Nephropathy!

Cigacial beard: breakthrough in the treatment of IGA-Nephropathy!

ERA Congress, Land - On June 5, 2025, the 62nd ERA Congress significant results for Zigakibart, a monoclonal anti-appril antibody. The new data from the phase-1/2 study demonstrate the long-term effectiveness and security of drug for patients with IGA-Nephropathy (IGAN), one of the most common forms of glomerular diseases and frequent cause of chronic kidney diseases. According to OTS develop with Igan Kidney failure.

Zigakibart aims to modulate the April signal path and reduce the production of the pathological GD-IGA1. In the ADU-CL-19 study, which included 40 adults with a bioptically confirmed Igan and persistent proteinuria, the patient received the medication every two weeks either intravenously or as a subcutaneous injection. In the 100th week of treatment, the proteinuria fell by 60 %compared to the starting value. Over 55 % of the study participants reached a proteinuria of less than 500 mg/24 h, while 31 % had less than 300 mg/24 h.

stable kidney function and safety profile

Another remarkable result of the study is that the estimated glomerular filtration rate (EGFR) remained stable in all subgroups. Treatment also led to a significant reduction in serum munoglobulins, including a decline of 74 % at IGA and GD-IGA1. The Cigacibart's security profile was rated as positive, and most of the unwanted events were easy to moderate. There were no cases of treatment-related severe infections or abrasions, although the study collided with a high COVID-19 prevalence. The most common undesirable events were infections.

For the future, promising developments are in sight: A phase 3 study entitled Beyond is currently being carried out to examine cigaci beard in a wider population group. This study focuses on primary proteinuria ends after 40 weeks as well as the long-term kidney function after 104 weeks Novartis .

risk factors and recommended measures

iga-nephropathy can be influenced by various risk factors such as obesity and smoking. Smoking increases the risk of terminal kidney failure at IGAN by a factor of 10. Recommended measures to reduce risk. Weight reduction, nicotine leave and regular endurance sports. Furthermore, the amount of drinking should be between 1.5 and 2 liters per day, while the salt intake should be reduced to less than 10 g a day. RAS inhibitors such as ACE inhibitors or angiotensin receptor blockers play a crucial role in the treatment and stabilization of kidney function Laekh .

In summary, the latest data on Zigakibart show the potential for a new, more effective treatment option in IGA-Nephropathy, while at the same time the need for a comprehensive risk assessment and lifestyle change for the affected patients is emphasized.